Evidence map›Paper›PMID 36545683›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Enabling the complete valorization of hybrid

Haojiang Qian, Yafeng Fan, Jiazhao Chen, Linsong He, Yongming Sun, Lianhua Li

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haojiang QianGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.
Yafeng FanGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.
Jiazhao ChenGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.
Linsong HeGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.
Yongming SunGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.
Lianhua LiGuangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conversion of lignocellulosic biomass into various high-value chemicals has been a rapid expanding research topic in industry and agriculture. Among them, alkaline removal and utilization of lignin are important for the accelerated degradation of biomass. Modern biorefinery has been focusing the vision on the advancement of economical, green, and environmentally friendly processes. Therefore, it is indispensable to develop cost-effective and simple biomass conversion technologies to obtain high-value products. In this study, the black liquor (BL) obtained from the alkaline pretreatment of biomass was added to polyvinyl alcohol (PVA) solution and used to prepare degradable ultraviolet (UV) shielding films, achieving direct and efficient utilization of the aqueous phase from alkaline pretreatment. This method avoids the extraction step of lignin fraction from black liquor, which can be directly utilized as the raw materials of films preparation. In addition, the direct use of alkaline BL results in films with similar UV-shielding properties, higher physical strength, and similar thermal stability compared with films made by commercial alkaline lignin. Therefore, this strategy is proposed for alkaline-pretreated biorefineries as a simple way to convert waste BL into valuable products and partially recover unconsumed sodium hydroxide to achieve as much integration of biomass and near zero-waste biorefineries as possible.

Indexed as

alkaline black liquorbiorefineryenergy grassfilmhybrid PennisetumligninUV-shielding

Identifiers

PMID36545683
PMCPMC9760701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.